Marks Group Wealth Management Inc Raises Stake in Becton, Dickinson and Company (NYSE:BDX)

Marks Group Wealth Management Inc lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 32,606 shares of the medical instruments supplier’s stock after buying an additional 1,161 shares during the period. Marks Group Wealth Management Inc’s holdings in Becton, Dickinson and Company were worth $7,861,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $26,000. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the period. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the second quarter worth approximately $45,000. Abound Wealth Management grew its holdings in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the period. Finally, Chilton Capital Management LLC increased its position in Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BDX shares. Stifel Nicolaus upped their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Raymond James cut their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Trading Up 1.3 %

NYSE:BDX opened at $237.30 on Wednesday. The stock has a market cap of $68.59 billion, a price-to-earnings ratio of 48.83, a price-to-earnings-growth ratio of 1.76 and a beta of 0.43. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $259.92. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The business’s 50-day simple moving average is $237.51 and its 200 day simple moving average is $235.12.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.